In a venetoclax (VEN)–ibrutinib combination treatment, the number of PD-1+CD8+ T cells, Tregs, and follicular helper T cells decreases more than fivefold, thereby reducing the immunosuppressive characteristics of CLL (97). The gene discussed is PDCD1; the disease is B-cell chronic lymphocytic leukemia.